Cat # changed from RMEE08R to E08
Type
Sandwich ELISA, Biotin-labelled antibody
Applications
Serum
Sample Requirements
10 µl/well
Shipping
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Storage/Expiration
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Calibration Curve
Calibration Range
0.031–2 ng/ml
Limit of Detection
0.01 ng/ml
Features
- Highly specific and sensitive assay for quantitative detection of IGFBP-2 in mouse and rat serum
- Recombinant mouse IGFBP-2 as standard
- Uses antibodies against complete mouse and rat IGFBP-2
- No sample extraction is required
- Detection limit: 0.01 ng/ml
Research topic
Growth hormone and factor-related products, Oncology, Animal studies
Summary
Insulin-like growth factors (IGFs) regulate the proliferation, differentation, apoptosis, cell adhesion and metabolism in various tissues and cell types. The IGF-1, which is produced mainly in liver under the influence of Growth Hormone (GH), regulates as hormone the linear growth of the bones and the process of sexual maturity, while IGF-II is mainly a growth factor of foetal tissue. The biological actions of IGF over the IGF-Type-1 receptor
are modulated variably through the IGF binding proteins (IGFBP-1 to-6). IGFBP-2 is, after IGFBP-3, the second most frequent IGFBP in the human blood. IGFs, especially tumor typical pro-IGF-forms and hormones
regulate the expression of IGFBP-2, GH effect is thereby inhibiting. At cellular level IGFBP-2 seems to stimulate
the proliferation and dissemination of solid tumors via an IGF-independent mechanism.
IGFBP-2 is an unglycosylated polypetide of 31.3 kDa, which forms binary IGF-complexes and shows no circadian rhythm in the circulation. The serum concentration of IGFBP-2 increases in fasting, after major surgery and after trauma, but the increasing of the concentration is most intensive in malignant diseases. The correlation of the IGFBP-2 level to the degree of progression is a striking feature in various tumor types as is the normalization of the IGFBP-serum levels after remission (5-10). During the GH-therapy, e.g. in short stature and in GH-abuse (doping) the IGFBP-2 level decreases. In Trisomy 18 IGFBP-2 in maternal serum is decreased and IGFBP-1 is increased; therefore the ratio IGFBP-2 /IGFBP-1 is a marker for this chromosome abnormality.
Transgenic organisms are a good opportunity to investigate the function of genes or proteins. The mouse or rat model is a well-suited system for investigation of the relevance of IGFBP-2 in physiological and pathological processes. Over expression of the IGFBP-2 gene in mice results in a weight reduction of 30% in spleen and moderately reduced weight in other organs. Effects of IGFBP-2 on the organism can be compensated through the modified expression of other IGF-Binding proteins. Especially in tumor biology the mouse and rat systems enable investigation of the systemic relevance of IGFBP-2. IGFBP-2 influences tumor cells as it induces catalase activity in adrenocortical cells. Furthermore IGFBP-2 interacts with tumor cells via its RGD-amino acid sequence and seems to stimulate cell invasion of glioma cells.
Instructions for Use (RUO)
Instructions for Use (RUO)
Safety Information (RUO)
MSDS (RUO)
MSDS (RUO)
Find documents for the lot